Biofourmis
Biofourmis is a global health technology company based in Boston, with additional offices in Singapore and India. Founded in 2015, the company specializes in AI-driven digital health solutions that enhance care delivery. Biofourmis aims to provide equitable access to healthcare, ensuring that individuals receive the right care regardless of their location. The company has developed a connected platform that monitors over 120 physiological biomarkers in real time. This platform enables early detection of health changes, facilitating proactive interventions and remote monitoring at hospital-level quality. Biofourmis offers services such as AI-driven remote patient monitoring, virtual provider networks, and support for clinical trial acceleration through digital biomarkers. Their solutions integrate data analytics and clinical workflows to deliver personalized and proactive care to health systems, payers, and biopharmaceutical companies. Led by CEO David Koretz, Biofourmis has experienced significant growth and investment, including a $300 million Series D funding round in 2022. The company is dedicated to improving patient outcomes and transforming healthcare delivery through innovative technology.
Work at Biofourmis in HR or recruiting? Claim this page
Headcount trend
Biofourmis went from 460 employees in Jul 2023 to 199 in Jun 2025. Jan to Jun 2025: 3 people joined, 65 left.
Headcount data through Jun 2025
Org structure
Headcount by department
Funding
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · Intel Capital
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
- Apr 2022 · Series D · $300M · General Atlantic, CVS Health, Openspace Ventures
Salaries at Biofourmis
All salaries13 salary profiles in India
Most reported roles
H-1B sponsorship
The department split adds up all the years listed above. FY2026 alone: 1 filings.
Peer reviews
Worked with someone at Biofourmis?
Anonymous peer reviews on OffTheRecord
Similar companies
Biofourmis FAQ
How many employees does Biofourmis have?
Biofourmis has about 199 employees, down 6.1% over the 3 months to Jun 2025.
Does Biofourmis sponsor H1B visas?
Yes. Biofourmis filed 1 H1B (LCA) application in FY2026, according to the latest U.S. Department of Labor disclosures. It was for a Engineering role.
What is Biofourmis's revenue per employee?
Biofourmis makes about $1.06M in revenue per employee, based on $210.1M annual revenue and 199 employees.
How much does Biofourmis pay?
6figr has 13 salary profiles for Biofourmis in India and 3 in the US, with pay broken down by role, level and gender on the Biofourmis salaries page. See Biofourmis salaries in India
How much funding has Biofourmis raised?
Biofourmis has raised $9.45B in total funding; its latest round was Series D in Apr 2022.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.
